не самое последнее в публикациях, но в полном тексте:
МИБИ как и ПЭТ дорого стоят, нужны специалисты в интерпретации и соотв. оборудование плюс не самая высокая точность:
The average cost of FDG-PET/CT is 1,132 USD/test [92] and it is similar to that for MIBI-Scan (1,648 USD/test) [48]. Both these procedures can only be performed in a highly specialized radiology and nuclear medicine Units, and they expose patients to radiations, that can be reduced if only the thyroid bed is scanned. However, for these reasons they are not recommended as routine screening methods.
FDG-PET/CT and MIBI-Scan showed a combination of intermediate values of both accuracy (65% and 79% respectively) and cost (both tests 1,000 - 2,000 USD).
поэтому авторами предлагается Galectin-3-ICC (GAL-3-ICC)
...GAL-3-ICC performed well as rule-out (sensitivity = 83%) and rule-in test (specificity = 85%), with good accuracy (84%)...
The clinically validated test-method with one of the lowest cost is, indeed, the GAL-3-ICC. The cost of this test-method (113 USD/test) is very competitive, compared with those estimated for FDG-PET/CT and is remarkably low compared to that reported for the molecular genetic test-methods (up to 20 times cheaper). For this reason it has been previously suggested that GAL-3-ICC could have a potential screening role, particularly in low-income Countries [31]. The present comparative analysis shows that GAL-3-ICC performs well both as an efficient rule-out and rule-in test-method, with rather good likelihood ratios and diagnostic accuracy. Visualization of sensitivity, specificity, likelihood ratios, accuracy and, more importantly, cost, in both two- and three-dimensional scatterplot diagrams, clearly indicates that GAL-3-ICC represents, at the present time, the candidate test-method to be chosen on large-scale basis. Moreover, GAL-3-ICC uses conventional FNA cytological substrates, is very easy to be performed in different clinical settings and does not require to be centralized in high specialized laboratories. Recently, we demonstrated that the sensitivity of GAL-3-ICC can be further improved by combination with clinical and ultrasound follow-up of negative nodules [93]. For all these reasons GAL-3-ICC can be proposed as a screening test-method for the preoperative characterization of indeterminate thyroid nodules in different clinical settings. GAL-3-ICC was recently included in a new algorithm for the management of patients with indeterminate FNA that was based on four different markers...
Comparative analysis of diagnostic performance, feasibility and cost of different test-methods for thyroid nodules with indeterminate cytology
[Ссылки доступны только зарегистрированным пользователям ]
|